Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Disease, Chronic Obstructive
Intervention: Atrovent® - inhalets (Drug)
Phase: N/A
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets
in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
Clinical Details
Official title: Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Change in overall severity of the clinical picture
Secondary outcome: Assessment of efficacy by investigator on a 4-point scaleAssessment of efficacy by patient on a 4-point scale Number of patients with adverse drug reactions Assessment of tolerability by investigator on a 4-point scale Assessment of tolerability by patient on a 4-point scale
Eligibility
Minimum age: 40 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients of both genders older than 40 years, who suffer from Chronic Obstructive
Pulmonary Disease
- Only patients who have not been treated with Atrovent® within the last year are to be
considered for inclusion
Exclusion Criteria:
- Contraindications listed in the Instructions for Use/Summary of Product
Characteristics for Atrovent® metered dose inhaler
Locations and Contacts
Additional Information
Starting date: February 2001
Last updated: September 8, 2014
|